Zobrazeno 1 - 10
of 2 779
pro vyhledávání: ''
Autor:
Erickson A, Carlos S. Moreno, Michelle M. Kouspou, Fred Saad, Michael S. Lewis, Onur Ertunc, Adeboye O. Osunkoya, Colm Morrissey, Bigler Sa, Tuomas Mirtti, Anne-Marie Mes-Masson, Stephen J. Freedland, Zhou X, Igor Vidal, Aud Svindland, Larry True, Tracy Jones, Ouellet, Mark Buzza, Wiley K, Tasken Ka, Pekka Taimen, Isla P. Garraway, Ariel H Achtman, Bova Sg, Angelo M. De Marzo, Bruce J. Trock, Dominique Trudel, Berge, Tarja Lamminen, Beatrice S. Knudsen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:715-727
Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Pl
Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 30:2167-2175
Background: Apart from the Epstein–Barr virus (EBV), the etiology of the hematologic malignancy Hodgkin lymphoma (HL) is not well defined. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are associated with some lymphoproliferative diseases wit
Autor:
Lakshmi Muthuswamy, Ling Huang, Raul S. Gonzalez, Jonah Cohen, Senthil K. Muthuswamy, Catherine Conahan, Supraja Narasimhan, Tyler M. Berzin, Mandeep S. Sawhney, Andrea J. Bullock, Mary Linton B. Peters, Sofia Perea, Roger B. Davis, Benjamin Schlechter, Bruno Bockorny, Dipikaa Akshinthala, Robert J. Besaw, Mark P. Callery, Douglas K. Pleskow, Leo L. Tsai, Martin P. Smith, Christine Maria Lim, Manuel Hidalgo, Tara S. Kent, Joseph E. Grossman
Publikováno v:
Clin Cancer Res
Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized
Autor:
Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, Ismet Srndic
Publikováno v:
Cancer Discovery, 12 (2)
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Autor:
Wuping Tang, Yi Li, Wei Zhou, Jinhui Hu, Bin Dai, Liyuan Qian, Hui Zhang, Zhi Xiao, Jianguo Wang, Tao Wu, Shouman Wang, Yunqi Wang, Q. Chen, Tiegang Tang, Xiaohong Yang, Jie Weng, Munawar Anwar, Dengjie Ouyang, Liping Liu, Peizhi Fan, Ning Xie, Maoliang Xiao, Xiaowen Gu, Jing Li, Bo Qiu, Zhongming Wang, Quchang Ouyang, Shan Zeng, Enxiang Zhou, Wenjun Yi, Chao Deng, Hailong Liu, Xiantao Li, Boning Ding, Lai Li, Lei Guo, Mingwen Liu, Gannong Chen
Publikováno v:
Clinical Cancer Research. 27:4634-4641
Purpose: Patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data to analyze
Autor:
Young Suk Park, Peter G. Mortimer, Kyoung-Mee Kim, Sophie E. Willis, Emma Dean, Claire Smith, Jung Yong Hong, Itziar Irurzun-Arana, Arsene-Bienvenu Loembé, Joon Oh Park, Iwanka Kozarewa, Andrew J. Pierce, Jeeyun Lee, Ho Yeong Lim, Simon Smith, Alienor Berges, Won Ki Kang, Hee Jin Cho, Seung Tae Kim, Se Hoon Park
Publikováno v:
Clinical Cancer Research. 27:4700-4709
Purpose: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein. Patients and Methods: Eligible patients with solid tumors, enriched for melanoma, received cer
Autor:
Stephen Moses, Kawango Agot, Michael G. Hudgens, Robert C. Bailey, Chris J.L.M. Meijer, Wenwen Mei, Hrishikesh Chakraborty, Danielle M. Backes, Eliane Rohner, Jennifer S. Smith
Publikováno v:
Cancer Epidemiology Biomarkers and Prevention, 30(6), 1139-1148. American Association for Cancer Research Inc.
Smith, J S, Backes, D M, Hudgens, M G, Mei, W, Chakraborty, H, Rohner, E, Moses, S, Agot, K, Meijer, C J L M & Bailey, R C 2021, ' Male circumcision reduces penile hpv incidence and persistence: A randomized controlled trial in Kenya ', Cancer Epidemiology Biomarkers and Prevention, vol. 30, no. 6, pp. 1139-1148 . https://doi.org/10.1158/1055-9965.EPI-20-1272
Cancer Epidemiol Biomarkers Prev
Smith, J S, Backes, D M, Hudgens, M G, Mei, W, Chakraborty, H, Rohner, E, Moses, S, Agot, K, Meijer, C J L M & Bailey, R C 2021, ' Male circumcision reduces penile hpv incidence and persistence: A randomized controlled trial in Kenya ', Cancer Epidemiology Biomarkers and Prevention, vol. 30, no. 6, pp. 1139-1148 . https://doi.org/10.1158/1055-9965.EPI-20-1272
Cancer Epidemiol Biomarkers Prev
Background: Male circumcision reduces the risk of human immunodeficiency virus infection in men. We assessed the effect of male circumcision on the incidence and natural history of human papillomavirus (HPV) in a randomized clinical trial in Kisumu,
Autor:
Hela Koka, Mustapha Abubakar, Jolanta Lissowska, Scott M. Lawrence, Montserrat Garcia-Closas, Jianming Ying, Ning Lyu, Jonine D. Figueroa, Xiaohong Rose Yang, Jing Zhang, Karun Mutreja, Changyuan Guo, Thomas U. Ahearn
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Purpose: Tumor-associated stroma is comprised of fibroblasts, tumor-infiltrating lymphocytes (TIL), macrophages, endothelial cells, and other cells that interactively influence tumor progression through inflammation and wound repair. Although gene-ex
Autor:
Troy Bremer, Jonas Bergh, Dick Folkvaljon, Lars A. Akslen, Fredrik Wärnberg, Viktoria Thurfjell, Arne Östman, Erik Holmberg, Per Karlsson, Aglaia Schiza, Carina Strell
Publikováno v:
Clinical Cancer Research. 27:3469-3477
Purpose: This study analyzes the potential of stromal platelet-derived growth factor receptor-beta (PDGFRb) expression as biomarker for radiotherapy (RT) benefit on ipsilateral breast events (IBE) in ductal carcinoma in situ (DCIS). Improved identifi
Autor:
Susan E. Hankinson, Serena C. Houghton
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Breast cancer is the most commonly diagnosed invasive cancer among women both globally and within the United States and the number one cause of cancer-related deaths among women globally ([1, 2][1]). Less than 1% of diagnosed breast cancers occur in